Safety, pharmacokinetics and exploratory exposure-response analysis of CX3002, a novel inhibitor of Xa, in Chinese healthy subjects.

Wenjun Chen,Zourong Ruan,Honggang Lou,Lu Wang,Rong Shao, Fenghua Li,Bo Jiang

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences（2023）

引用 1|浏览5

暂无评分

摘要

CX3002 was well tolerated and resulted in dose-related anti-Xa activity across the dose range. The PK of CX3002 were predictable, and correlated with PD effects. Continued clinical investigation of CX3002 was supported. Chinadrugtrials.org.cn identifier: CTR20190153.

查看译文

关键词

CX3002,Exposure-response,Healthy subjects,Pharmacokinetics,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要